Health Medicine Chemistry Company

HMC (Health Medicine Chemistry) is a clinical-stage biotechnology company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the discovery of small molecule and peptide-based treatments for prevalent conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). HMC's lead programs target key metabolic pathways, including the GLP-1 receptor and FGF21 signaling, to improve glycemic control and promote weight loss. By leveraging advanced medicinal chemistry, the company aims to provide next-generation therapeutic options with improved efficacy and safety profiles for patients worldwide.